Article Sidebar
Views PDF: 201
CHARACTERISTICS OF CLINICAL AND PARACLINICAL OF NON-SMALL CELL LUNG CANCER PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT AND BRAIN METASTASIS TREATED AT BACH MAI HOSPITAL
Main Article Content
Abstract
Object: Characterizing of non-small cell lung cancer patients with epidermal growth factor receptor mutant and brain metastasis treated at Bach Mai Hospital. Patient and Methods: Retrospective, descriptive, cross-sectional, studying on 53 epidermal growth factor receptor, brain metastasis of mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors plus Rotating Gamma System Radiosurgery at the Nuclear Medicine and Oncology Center of Bach Mai Hospital from January 2016 to December 2020. Results: 50.9% male, male/female ratio: 1.04/1, mainly aged 50-69 (73.6%). 43.4% of patients smoked, only found in men. Common symptoms were respiratory symptoms (54.7%), followed by neurological symptoms (39.6%). Most of the patients had a PS ECOG score from 0 to 1 (81.1%). Stage T1-2 saw 64.2%, lymph node metastasis (58.5%), brain metastases often combined with other organs (64.2%) of which bone metastases most commonly (49.1%), followed by metastases in lung, pleura (28.3%), adrenal gland (5.7%), liver (3.7%). Characteristics of brain metastases: Single-focal metastasis occurred in 47%, the location or metastasis was in the cerebral hemisphere (79.2%), size from 1-20mm accounted for the highest rate (69.9%), small size 1-10mm accounted for 20.1%. The majority of patients with Del19 mutant (67.9%), Del 19/L858R = 2.77/1. Compared with the exon 21 mutation, the Del 19 mutation was more common in the female group (63.9%) the difference was statistically significant with p=0.005. Most of the patients had abnormal CEA, cyfra 21-1 concentration (81.8% and 70.3%). Bone metastasis was closely associated with abnormally elevated CEA with p=0.047. Conclusion: non-small cell lung cancer patients with epidermal growth factor receptor mutant and brain metastasis had a balanced male/female ratio, Del 19 mutations were the majority and more common in women than men. CEA has high sensitivity in predicting systemic metastases, especially bone metastases.
Article Details
Keywords
brain metastasis, lung cancer, EGFR mutation, patient characteristics, CEA
References
2. Davis F G, Dolecek T A, McCarthy B J, et al (2012). "Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data". Neuro Oncol, 14 (9), 1171-1177.
3. Mai Trọng Khoa (2020). Hướng dẫn chẩn đoán và điều trị một số bệnh lý ung bướu, Nhà xuất bản Y học,
4. Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, et al (2015). "The incidence and mortality of lung cancer and their relationship to development in Asia". Transl Lung Cancer Res, 4 (6), 763-774.
5. Magnuson W J, Lester-Coll N H, Wu A J, et al (2017). "Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis". J Clin Oncol, 35 (10), 1070-1077.
6. Phạm Văn Thái (2014). Nghiên cứu điều trị ung thư phổi không tế bào nhỏ di căn não bằng hoá xạ trị, Luận án Tiến sỹ y học, Trường Đại học y Hà Nội.
7. Kelly W J, Shah N J, Subramaniam D S (2018). "Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer". Front Oncol, 8 208.
8. Lee D S, Kim S J, Kang J H, et al (2014). "Serum Carcinoembryonic Antigen Levels and the Risk of Whole-body Metastatic Potential in Advanced Non-small Cell Lung Cancer". J Cancer, 5 (8), 663-669.